Coherus Oncology (CHRS) Cash & Equivalents (2016 - 2025)
Coherus Oncology (CHRS) has disclosed Cash & Equivalents for 14 consecutive years, with $88.9 million as the latest value for Q4 2025.
- Quarterly Cash & Equivalents fell 29.45% to $88.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $88.9 million through Dec 2025, down 29.45% year-over-year, with the annual reading at $88.9 million for FY2025, 29.45% down from the prior year.
- Cash & Equivalents hit $88.9 million in Q4 2025 for Coherus Oncology, down from $103.4 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $417.2 million in Q4 2021 to a low of $16.1 million in Q1 2023.
- Historically, Cash & Equivalents has averaged $186.2 million across 5 years, with a median of $142.6 million in 2024.
- Biggest five-year swings in Cash & Equivalents: plummeted 95.04% in 2023 and later skyrocketed 1509.01% in 2024.
- Year by year, Cash & Equivalents stood at $417.2 million in 2021, then tumbled by 84.77% to $63.5 million in 2022, then soared by 61.91% to $102.9 million in 2023, then grew by 22.45% to $126.0 million in 2024, then decreased by 29.45% to $88.9 million in 2025.
- Business Quant data shows Cash & Equivalents for CHRS at $88.9 million in Q4 2025, $103.4 million in Q3 2025, and $216.9 million in Q2 2025.